Changing Market Needs in Oncology Following the Launch of Immune Checkpoint Antibodies
First written in FY2017-Q3. 23 of 24 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「In recent years, the focus of competition in anticancer drug development has shifted to immune checkpoint inhibitor antibodies and combination therapies involving them.」
The shift in development competition toward immune checkpoint inhibitor antibodies and combination therapies continues to be recognized as part of the environment relevant to CBP501 development. - FY2025-H1RestatedAnnual report
「In recent years, the emergence of immune checkpoint inhibitor antibodies has brought about changes in market needs and the development environment in the cancer field that could be described as a paradigm shift. Management believes that this change in needs represents a once-in-a-lifetime opportunity for the company, which has the candidate compound CBP501, potentially capable of playing an important role in combination with immunotherapeutic anticancer drugs, and has accumulated basic research results in cancer immunology.」
The company continues to view changes in market needs and the development environment following the emergence of immune checkpoint inhibitor antibodies as an opportunity for the combination development of CBP501. - FY2024-Q3RestatedAnnual report
「In recent years, the emergence of immune checkpoint inhibitor antibodies has brought about changes in market needs and the development environment in the cancer field that could be described as a paradigm shift. Management believes that this change in needs represents a once-in-a-lifetime opportunity for the company, which has the candidate compound CBP501, potentially capable of playing an important role in combination with immunotherapeutic anticancer drugs, and has accumulated basic research results in cancer immunology.」
The company continues to view changes in market needs and the development environment following the emergence of immune checkpoint inhibitor antibodies as an opportunity for the combination development of CBP501. - FY2024-Q1RestatedAnnual report
「In recent years, the emergence of immune checkpoint inhibitor antibodies has brought about changes in market needs and the development environment in the cancer field that could be described as a paradigm shift. Management believes that this change in needs represents a once-in-a-lifetime opportunity for the company, which has the candidate compound CBP501, potentially capable of playing an important role in combination with immunotherapeutic anticancer drugs, and has accumulated basic research results in cancer immunology.」
The company continues to view changes in market needs and the development environment following the emergence of immune checkpoint inhibitor antibodies as an opportunity for the combination development of CBP501. - FY2023-Q3RestatedAnnual report
「In recent years, the emergence of immune checkpoint inhibitor antibodies has brought about changes in market needs and the development environment in the cancer field that could be described as a paradigm shift. Management believes that this change in needs represents a once-in-a-lifetime opportunity for the company, which has the candidate compound CBP501, potentially capable of playing an important role in combination with immunotherapeutic anticancer drugs, and has accumulated basic research results in cancer immunology.」
The company continues to view changes in market needs and the development environment following the emergence of immune checkpoint inhibitor antibodies as an opportunity for the combination development of CBP501. - FY2023-Q2RestatedAnnual report
「In recent years, the emergence of immune checkpoint inhibitor antibodies has brought about changes in market needs and the development environment in the cancer field that could be described as a paradigm shift. Management believes that this change in needs represents a once-in-a-lifetime opportunity for the company, which has the candidate compound CBP501, potentially capable of playing an important role in combination with immunotherapeutic anticancer drugs, and has accumulated basic research results in cancer immunology.」
The company continues to view changes in market needs and the development environment following the emergence of immune checkpoint inhibitor antibodies as an opportunity for the combination development of CBP501. - FY2022RestatedAnnual report
「In recent years, the focus of competition in anticancer drug development has shifted to immune checkpoint inhibitor antibodies and combination therapies involving them.」
The company reconfirms that the shift in development competition toward immune checkpoint inhibitor antibodies and combination therapies is an aspect of the operating environment related to CBP501 development. - FY2022-Q3RestatedAnnual report
「In recent years, the emergence of immune checkpoint inhibitor antibodies has brought about changes in market needs and the development environment in the cancer field that could be described as a paradigm shift.」
The company reconfirms that changes in market needs and the development environment following the emergence of immune checkpoint inhibitor antibodies are an important aspect of the operating environment related to the combination development of CBP501. - FY2022-Q2RestatedAnnual report
「In recent years, the emergence of immune checkpoint inhibitor antibodies has brought about changes in market needs and the development environment in the cancer field that could be described as a paradigm shift.」
The company reconfirms that changes in market needs and the development environment following the emergence of immune checkpoint inhibitor antibodies are an important aspect of the operating environment related to the combination development of CBP501. - FY2021RestatedAnnual report
「In recent years, the focus of competition in anticancer drug development has shifted to immune checkpoint inhibitor antibodies and combination therapies involving them.」
The company reconfirms that the shift in development competition toward immune checkpoint inhibitor antibodies and combination therapies is an important aspect of its operating environment. - FY2021-Q3RestatedAnnual report
「In recent years, the launch of immune checkpoint inhibitor antibodies has brought about changes in market needs in the cancer field that could be described as a paradigm shift.」
The company reconfirms that changes in market needs following the launch of immune checkpoint inhibitor antibodies are an important aspect of the operating environment related to the combination development of CBP501. - FY2021-Q2RestatedAnnual report
「In recent years, the launch of immune checkpoint inhibitor antibodies has brought about changes in market needs in the cancer field that could be described as a paradigm shift.」
The company reconfirms that changes in market needs following the launch of immune checkpoint inhibitor antibodies are an important aspect of the operating environment related to the combination development of CBP501. - FY2021-Q1RestatedAnnual report
「In recent years, the launch of immune checkpoint inhibitor antibodies has brought about changes in market needs in the cancer field that could be described as a paradigm shift.」
The company reconfirms that changes in market needs following the launch of immune checkpoint inhibitor antibodies are an important aspect of the operating environment related to the combination development of CBP501. - FY2020RestatedAnnual report
「In recent years, the focus of competition in anticancer drug development has shifted to immune checkpoint inhibitor antibodies and combination therapies involving them.」
The company reconfirms that the shift in development competition toward immune checkpoint inhibitor antibodies and combination therapies is an important aspect of its operating environment. - FY2020-Q3RestatedAnnual report
「In recent years, the launch of immune checkpoint inhibitor antibodies has brought about changes in market needs in the cancer field that could be described as a paradigm shift. Management believes that this change in needs represents a once-in-a-lifetime opportunity for the company, which has the candidate compound CBP501, potentially capable of playing an important role in combination with immunotherapeutic anticancer drugs, and has accumulated basic research results related to it.」
The company reconfirms its view that changes in market needs following the launch of immune checkpoint inhibitor antibodies represent an opportunity for the combination development of CBP501. - FY2020-Q2RestatedAnnual report
「In recent years, the launch of immune checkpoint inhibitor antibodies has brought about changes in market needs in the cancer field that could be described as a paradigm shift.」
The company reconfirms that changes in market needs following the launch of immune checkpoint inhibitor antibodies are an important aspect of the operating environment related to the combination development of CBP501. - FY2020-Q1RestatedAnnual report
「In recent years, the launch of immune checkpoint inhibitor antibodies has brought about changes in market needs in the cancer field that could be described as a paradigm shift.」
The company reconfirms its view that changes in market needs following the launch of immune checkpoint inhibitor antibodies represent an opportunity for the combination development of CBP501. - FY2019-Q3RestatedAnnual report
「In recent years, the launch of immune checkpoint inhibitor antibodies has brought about changes in market needs in the cancer field that could be described as a paradigm shift. Management believes that this change in needs represents a once-in-a-lifetime opportunity for the company, which has the candidate compound CBP501, potentially capable of playing an important role in combination with immunotherapeutic anticancer drugs, and has accumulated basic research results related to it.」
The company reconfirms its view that changes in market needs following the launch of immune checkpoint inhibitor antibodies represent an opportunity for the combination development of CBP501. - FY2019-Q2RestatedAnnual report
「In recent years, the launch of immune checkpoint inhibitor antibodies has brought about changes in market needs in the cancer field that could be described as a paradigm shift. Management believes that this change in needs represents a once-in-a-lifetime opportunity for the company, which has the candidate compound CBP501, potentially capable of playing an important role in combination with immunotherapeutic anticancer drugs, and has accumulated basic research results related to it.」
The company reconfirms its view that changes in market needs following the launch of immune checkpoint inhibitor antibodies represent an opportunity for the combination development of CBP501. - FY2019-Q1RestatedAnnual report
「In recent years, the launch of immune checkpoint inhibitor antibodies has brought about changes in market needs in the cancer field that could be described as a paradigm shift. Management believes that this change in needs represents a once-in-a-lifetime opportunity for the company, which has the candidate compound CBP501, potentially capable of playing an important role in combination with immunotherapeutic anticancer drugs, and has accumulated basic research results related to it.」
The company reconfirms its view that changes in market needs following the launch of immune checkpoint inhibitor antibodies represent an opportunity for the combination development of CBP501. - FY2018-Q3RestatedAnnual report
「In recent years, the launch of immune checkpoint inhibitor antibodies has brought about changes in market needs in the cancer field that could be described as a paradigm shift. Management believes that this change in needs represents a once-in-a-lifetime opportunity for the company, which has the candidate compound CBP501, potentially capable of playing an important role in combination with immunotherapeutic anticancer drugs, and has accumulated basic research results related to it.」
The company reconfirms its view that changes in market needs following the launch of immune checkpoint inhibitor antibodies represent an opportunity for the combination development of CBP501. - FY2018-Q2RestatedAnnual report
「In recent years, the launch of immune checkpoint inhibitor antibodies has brought about changes in market needs in the cancer field that could be described as a paradigm shift. Management believes that this change in needs represents a once-in-a-lifetime opportunity for the company, which has the candidate compound CBP501, potentially capable of playing an important role in combination with immunotherapeutic anticancer drugs, and has accumulated basic research results related to it.」
The company reconfirms its view that changes in market needs following the launch of immune checkpoint inhibitor antibodies represent an opportunity for the combination development of CBP501. - FY2017RestatedAnnual report
「In recent years, the focus of competition in anticancer drug development has shifted to immune checkpoint inhibitor antibodies.」
The company continues to regard the shift in market and development competition toward immune checkpoint inhibitor antibodies as an important aspect of its operating environment. - FY2017-Q3First statedAnnual report
「In recent years, the launch of immune checkpoint antibodies has brought about changes in market needs in the cancer field that could be described as a paradigm shift. Management believes that this change in needs represents a once-in-a-lifetime opportunity for the company, which has the candidate compound CBP501, potentially capable of playing an important role in combination with immunotherapeutic anticancer drugs, and has accumulated basic research results related to it.」
The company recognizes that market needs in cancer have changed significantly following the launch of immune checkpoint antibodies and positions this as an opportunity for CBP501.